Nikolić Heitzler Vjeran, Pavlov Marin, Babić Zdravko, Bulj Nikola
Coronary Unit, Sestre milosrdnice University Hospital, Zagreb, Croatia.
Acta Med Croatica. 2009 Feb;63(1):117-9.
By establishing the Croatian network of primary PCI more patients can now be treated by this method every year. Nevertheless, therapeutic success depends on appropriate, i.e. complete antithrombotic therapy. On the other hand, about half of inhabitants of Croatia have not yet been covered with primary PCI network. Aspirin has an established role in antithrombotic therapy, demonstrated in numerous clinical studies. Thienopirydines, especially clopidogrel, have improved the outcome of interventional cardiology. GP IIb/IIIa receptor inhibitors, despite their high price, pave their way into our daily practice. Heparin is an essential part of therapy for almost all acute coronary syndrome scenarios, but the role of low-molecular heparins is yet to be clarified. Fibrinolytic therapy still "saves lifes". By improving new fibrinolytics, they have become easier to use, entail less side effects and are more efficient.
通过建立克罗地亚直接经皮冠状动脉介入治疗网络，现在每年可以用这种方法治疗更多患者。然而，治疗成功取决于适当的，即完整的抗血栓治疗。另一方面，克罗地亚约有一半居民尚未被直接经皮冠状动脉介入治疗网络覆盖。阿司匹林在抗血栓治疗中具有既定作用，这在众多临床研究中得到了证实。噻吩吡啶类药物，尤其是氯吡格雷，改善了介入心脏病学的治疗效果。糖蛋白IIb/IIIa受体抑制剂尽管价格高昂，但已进入我们的日常临床实践。肝素几乎是所有急性冠状动脉综合征治疗方案中必不可少的一部分，但低分子肝素的作用尚待阐明。溶栓治疗仍然“拯救生命”。通过改进新型溶栓药物，它们使用起来变得更加容易，副作用更少且效率更高。
